Quality of life in patients with implantable cardioverter defibrillators Author: Camelia Tănăsuc Coordinator: Professor Doctor Dan Dobreanu Coauthors:

Slides:

Advertisements

Similar presentations

Patient-reported Measures: KCCQ and CHF outcomes Aanand D. Naik, MD Houston Health Services Research and Development Center of Excellence.

Advertisements

Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need

Long term effect of self-regulation education on use of inhaled anti-inflammatories and short-acting bronchodilators Clark, NM, Gong, M, Wang, S, Lin,

Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)

IMPANTABLE CARDIOVERTER DEFIBRILLATORS (ICDs) Janet McComb Freeman Hospital Newcastle upon Tyne.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,

TEMPLATE DESIGN © Prevalence of educational qualifications and access to information technologies in patients with acute.

Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT.

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.

Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.

Association of Health Plan’s HEDIS Performance with Outcomes of Enrollees with Diabetes Sarah Hudson Scholle, MPH, DrPH April 9, 2008.

Functional Impairment and Depressive Symptoms: Mitigating Effects of Trait Hope Jameson K. Hirsch, Ph.D. 1,2, S. Kaye, B.S. 1, & Jeffrey M. Lyness, M.D.

Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.

Author: Moldovan Carmen Co-authors: Opincariu Diana Balan Daniel University of Medicine and Pharmacy Tg. Mures Cardiology Clinic, Mures Emergency Clinical.

Monthly Journal article review: Vimmi Kang PGY 2

Risk assessment for VTE Dr Roopen Arya King’s College Hospital.

Long-term functional deficiencies of ICU-acquired weakness: a prospective study I Patsaki, G Sidiras, V Gerovasili, A Kouvarakos, E Polimerou, G Mitsiou,

Grace Thacker Xavier University of Louisiana LSUHC – Internal Medicine

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,

Nabhan C et al. Proc ICML 2013;Abstract 102.

CoRPS Center of Research on Psychology in Somatic diseases Multiple myeloma survivors experience a low quality of life and many disease-specific complaints:

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.

CoRPS Center of Research on Psychology in Somatic diseases Poor health status in implantable cardioverter defibrillator patients: Shock, patient pre implantation.

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Implantable Cardioverter Defibrillators and Quality.

Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.

CoRPS Disclosures None. CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

DIABETES AS A RISK FACTOR FOR COGNITIVE DECLINE IN OLDER PATIENTS F. Limongi, A. Marseglia, S. Maggi, M. Noale, G. Romanato, P. Siviero, G. Crepaldi CNR,

The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:

Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Impact of QRS Duration on Clinical Event Reduction.

Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.

CoRPS Center of Research on Psychology in Somatic diseases Depression is associated with a 2-fold independent risk of mortality in implantable cardioverter.

Author Disclosure Sex Differences in the Characteristics of Patients Receiving ICD Therapy for the Primary Prevention of Sudden Cardiac Death –Stacie L.

Defibrillator in Acute Myocardial Infarction Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Drs. Stewart Connelly.

Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.

Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.

Copyright © 2011 American Medical Association. All rights reserved.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Quality of life as predictor for the development of.

Defibrillator in Acute Myocardial Infarction Trial

Figure 1 Study flow chart.

Emerging Data on ACS Management From ACC

Managing Hereditary Angioedema

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

(pnoninferiority < )

European Heart Association Journal 2007 April

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD Heart Rhythm

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

Ranolazine in Microvascular Dysfunction

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Baseline Characteristics of the Patients – Part I

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Presentation transcript:

Quality of life in patients with implantable cardioverter defibrillators Author: Camelia Tănăsuc Coordinator: Professor Doctor Dan Dobreanu Coauthors: Diana Costa,Ioana u,Roxana Rudzik

Objective the aim of this study was to assess quality of life (QOL) in relationship to clinical data in patients with implanted ICD

Material and Method

The Medical Outcome Trust Short Form (SF-12v2) Health Survey

Clinical data age myocardial infarction heart failure

Results PSS physical status score MSS mental status score mean±SD baseline 41±9.6950±12.78 median40.548

‘Low’ PSS group: 8 patients ; PSS score ≤40.5; older (51± 8.35 vs 46± 21.69) ; severe heart failure ; myocardial infarction ; MSS score also lower (45±14.83 vs 54±10.10).

‘Low’ MSS group: 8 patients ; MSS score ≤48 ; older (53±13.72 vs 44±17.96) ; severe heart failure ; myocardial infarction ; PSS was lower (39± 8.91 vs 60± 5.99, p= ).

Discussions except PSS between ‘low’ and ‘high’ MSS group, the differences are not statistically significant. the type and number of ICD therapies do not appear to influence any PSS or MSS.

Discussions Piotrowicz et al.¹ found that ‘low’MSS or PSS group have severe heart failure, NYHA II- IV, but were younger. neither PSS nor MSS was significantly associated with ICD-therapy. 1. Katarzyna Piotrowicz, Katia Noyes, Jeffrey M. Lyness, Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. European Heart Journal (2007) 28, 601–607

Discussions Schron et al.² showed that any kind of shock, compared with receiving no shocks, is associated with significant declines in mental well-being and physical functioning. 2.Eleanor B. Schron, Derek V. Exner, Qing Yao,et al. Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial: Impact of Therapy and Influence of Adverse Symptoms and Defibrillator Shocks. Circulation. 2002;105:

The limitation of this study includes: small number of patients; short time of running of trial; interpretation of SF-12 score.

Conclusions the link between clinical characteristics and QOL in patients with ICD are still incompletely defined. following more patients over extended periods may indicate that the clinical features correlate significantly with QOL change.

Thank you for your attention!